Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Mercaptopurine
Drug ID BADD_D01392
Description An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
Indications and Usage For remission induction and maintenance therapy of acute lymphatic leukemia.
Marketing Status approved
ATC Code L01BB02
DrugBank ID DB01033
KEGG ID D00161; D04931
MeSH ID D015122
PubChem ID 667490
TTD Drug ID D09UZO
NDC Product Code 62991-2899; 69076-913; 15308-0712; 12780-0299; 0054-4581; 0378-3547
UNII E7WED276I5
Synonyms Mercaptopurine | 6H-Purine-6-thione, 1,7-dihydro- | 6-Mercaptopurine Monohydrate | 6 Mercaptopurine Monohydrate | 6-Thiopurine | 6 Thiopurine | 1,7-Dihydro-6H-purine-6-thione | 6-Mercaptopurine | 6 Mercaptopurine | 6-Thiohypoxanthine | 6 Thiohypoxanthine | Purinethol | Puri-Nethol | Mercaptopurina Wellcome | Leupurin | BW 57-323H | BW 57 323H | BW 57323H | Purimethol | Mecaptopurine Anhydrous
Chemical Information
Molecular Formula C5H4N4S
CAS Registry Number 50-44-2
SMILES C1=NC2=C(N1)C(=S)N=CN2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thinking abnormal19.10.03.001; 17.02.05.023--Not Available
Thrombocytopenia01.08.01.0020.005725%Not Available
Ulcer08.03.06.001--Not Available
Ureteric obstruction20.06.01.0050.001561%Not Available
Uveitis10.02.01.023; 06.04.03.003--
Venoocclusive liver disease12.02.09.039; 24.04.07.002; 09.01.06.0020.001561%
Vomiting07.01.07.0030.016967%
Poor venous access24.03.02.017--Not Available
General physical health deterioration08.01.03.0180.001041%Not Available
Anal haemorrhage24.07.02.029; 07.12.03.004--
Subileus07.13.01.004--Not Available
Lupus-like syndrome23.03.02.004; 15.06.02.004; 10.04.03.003--Not Available
Nodular regenerative hyperplasia09.01.04.0040.003851%Not Available
Hyperuricosuria20.02.01.019--Not Available
Cytokine release syndrome10.02.01.0100.001041%
Lymphatic disorder01.09.01.003--Not Available
Phlebosclerosis24.04.02.0030.001041%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Infusion site pain08.02.05.014; 12.07.05.002--Not Available
Transaminases increased13.03.04.036--Not Available
Foetal death08.04.01.011; 18.01.02.003--
Ocular icterus09.01.01.007; 06.08.03.009; 01.06.04.0070.001041%Not Available
Hyperinsulinaemia05.06.03.005; 14.06.03.0050.001041%Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Breast disorder21.05.04.004--Not Available
Feeding disorder19.09.01.003; 14.03.02.0030.001041%Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
Malnutrition14.03.02.004--Not Available
Therapeutic reaction time decreased08.06.01.015--Not Available
Decreased appetite14.03.01.005; 08.01.09.0280.005205%
The 7th Page    First    Pre   7 8 9    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene